Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR known ✓ | P25105 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.30 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6890861 | 0.95 | BRD4 (0.33) | BRD4CREBBP | |
| Hydrochloric Acid SCHEMBL6892092 | 0.91 | CYP11B1 (0.33) | KIF11PARP1 | |
| Hydrochloric Acid SCHEMBL6892494 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL6895151 | 0.90 | CHRNB2 (0.31) | BRD4 | |
| Hydrochloric Acid SCHEMBL6892926 | 0.89 | RXRA (0.30) | KIF11 | |
| Hydrochloric Acid SCHEMBL5274044 | 0.87 | BRD4 (0.34) | BRD4CREBBPKIF11PARP1PTAFR | |
| Hydrochloric Acid SCHEMBL6891548 | 0.87 | CYP11B1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL6893825 | 0.86 | BRD4 (0.32) | BRD4CREBBP | |
| Hydrochloric Acid SCHEMBL6892040 | 0.86 | EDNRB (0.32) | — | |
| Hydrochloric Acid SCHEMBL6892793 | 0.86 | CYP3A4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784305-B2 | DERIVATIVES OF ZIRCONOCENE DICHLORIDE IN WHICH THE TWO SUBSTITUTED INDENYL GROUPS ARE JOINED TO ONE ANOTHER VIA A BRIDGE CAN, OWING TO THEIR CONFORMATIONAL RIGIDITY, BE USED AS CATALYSTS FOR THE STEREOSPECIFIC POLYMERIZATION OF OLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | EQUISTAR CHEMICALS, LP | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199703-A1 | Method for producing alkyl-bridged ligand systems and transition metal compounds | ABL1, ICMT, ORAI2 | PTAFR 2781/4885BRD4 64/4885CREBBP 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.